Domestic pharmaceutical companies are divided over the development of the COVID-19 vaccine. After the introduction of Pfizer, Moderna Vaccine, some companies stopped developing due to reduced commerciality and difficulties in recruiting clinical participants. Companies that are newly developing in preparation of the coronavirus are steadily appearing, creating conflicting scenes.

◆ Three new clinical trials after approval of Pfizer vaccine

According to the pharmaceutical industry on the 14th, Genematrix applied for a patent for a candidate substance for the next-generation COVID-19 vaccine. The company confirmed its effectiveness on various mutations such as delta and omikron, and